Savel'ev V S, Iablokov E G, Il'in V N, Kirienko A I, Leont'ev S G
Grudn Khir. 1989 May-Jun(3):25-34.
Analysis of the results of using fibrinolysis activators in 196 patients with massive embolism of the pulmonary arteries was undertaken to choose the optimum method of thrombolytic therapy. High doses of fibrinolysis activators (from 5,000,000 to 7,000,000 U) were used in 127 cases and low doses (from 125,000 to 3,000,000 U) in combination with heparin and disaggregating agents in the remaining 69 cases. A cava-filter was implanted in 161 patients before beginning treatment. Obvious advantages of thrombolytic therapy of massive pulmonary embolism with high doses of fibrinolysis activators were revealed in the process of treatment. They consist in quicker restoration of continuity of the pulmonary arteries, which leads to rapid removal of hypertension in pulmonary circulation and reduction of the number of deaths from acute cardiopulmonary failure. Treatment with such doses does not lead to an increase of the number of hemorrhagic complications, which makes possible surgical prevention of recurrent pulmonary embolism by cava-filter implantation.
对196例大面积肺动脉栓塞患者使用纤维蛋白溶解激活剂的结果进行了分析,以选择最佳的溶栓治疗方法。127例患者使用了高剂量的纤维蛋白溶解激活剂(500万至700万单位),其余69例患者使用低剂量(12.5万至300万单位)并联合肝素和抗聚集剂。161例患者在开始治疗前植入了下腔静脉滤器。在治疗过程中发现,高剂量纤维蛋白溶解激活剂治疗大面积肺栓塞具有明显优势。这些优势包括肺动脉连续性更快恢复,从而迅速消除肺循环中的高血压并减少急性心肺衰竭导致的死亡人数。使用此类剂量治疗不会导致出血并发症数量增加,这使得通过植入下腔静脉滤器对复发性肺栓塞进行手术预防成为可能。